Amylyx Pharmaceuticals In... (AMLX)
5.18
-0.18 (-3.36%)
At close: Apr 28, 2025, 12:51 PM
-3.36% (1D)
| Bid | 5.18 |
| Market Cap | 459.4M |
| Revenue (ttm) | 87.37M |
| Net Income (ttm) | -301.74M |
| EPS (ttm) | -4.43 |
| PE Ratio (ttm) | -1.17 |
| Forward PE | -2.77 |
| Analyst | Hold |
| Ask | 5.19 |
| Volume | 271,030 |
| Avg. Volume (20D) | 800,183 |
| Open | 5.36 |
| Previous Close | 5.36 |
| Day's Range | 5.07 - 5.40 |
| 52-Week Range | 1.57 - 7.27 |
| Beta | -0.53 |
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. ...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 7, 2022
Employees 123
Stock Exchange NASDAQ
Ticker Symbol AMLX
Website https://amylyx.com
Analyst Forecast
According to 5 analyst ratings, the average rating for AMLX stock is "Hold." The 12-month stock price forecast is $7, which is an increase of 35.00% from the latest price.
Stock Forecasts5 months ago
+11.34%
Amylyx Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
9 months ago
+25.45%
Amylyx Pharmaceuticals shares are trading higher after the company announced that it acquired avexitide from Eiger BioPharmaceuticals.
